Clinical trials
Leukemia, Lymphocytic, Chronic, B-Cell clinical trials
Below are recruiting leukemia, lymphocytic, chronic, b-cell clinical trials, each written for real people, not researchers. We’re tracking 134 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05947851RecruitingPhase 3
Nemtabrutinib plus venetoclax versus standard add-on therapy
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Springdale, ArkansasAges 18 years+ - NCT06594939RecruitingPhase 2
Combination chemo for elderly DLBCL patients
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
Milwaukee, WisconsinAges 70 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT06846671RecruitingPhase 3
Study of a new drug for CLL or SLL
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Jonesboro, ArkansasAges 18 years+ - NCT07775508RecruitingPhase 1
Car t cell therapy for relapsed or refractory b cell lymphoma
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
BeijingAges 18–75 - NCT05006716RecruitingPhase 1/Phase 2
Testing a new drug for certain B-cell blood cancers
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Birmingham, AlabamaAges 18 years+ - NCT07221500RecruitingPhase 2
Study of NX-5948 for advanced CLL or SLL
This trial tests an experimental drug called NX-5948 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments. It's for those who have already tried a BTK inhibitor and a BCL-2 inhibitor.
Duarte, CaliforniaAges 18 years+ - NCT06980116RecruitingPhase 1
Finding the right dose of EXS73565 for relapsed B-cell cancers
This study tests a new oral medication (EXS73565) for people with B-cell blood cancers that came back or didn't respond to standard treatments. It aims to find the best dose and check if it's safe and helpful.
TbilisiAges 18 years+ - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT07750886Recruiting
Collecting samples for lymphoma research
This study collects blood and tumor tissue samples from people newly diagnosed with aggressive non-Hodgkin lymphoma who will receive standard chemotherapy. The goal is to improve future tests for detecting minimal residual disease (tiny amounts of cancer left after treatment).
Austin, TexasAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT06735664RecruitingPhase 1
Zanubrutinib and odronextamab for Richter's transformation
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT05366218RecruitingPhase 1/Phase 2
Tafasitamab for kids with high-risk B-cell leukemia after relapse
This Phase 1/2 study tests tafasitamab in children and teens with B-lineage acute lymphoblastic leukemia (ALL) that has come back or did not respond. It is mainly for patients with specific high-risk leukemia changes and/or leukemia markers that stay after stem cell transplant or CAR T-cell therapy.
Freiburg im Breisgau, Baden-WurttembergAges 3–18 - NCT05869279RecruitingPhase 1/Phase 2
Study of donor immune cells for B-cell blood cancers
This Phase 1/2 study tests an “allogeneic” donor T-cell therapy (CARCIK-CD19) for children and adults with certain B-cell lymphomas and CLL who have tried multiple treatments. It may help by targeting cancer cells using engineered immune cells, but eligibility is complex and depends on donor availability and medical readiness.
Bergamo, BGAges 1 year+ - NCT07246707RecruitingPhase 1
KSV01 injection for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
HangzhouAges 18–80 - NCT06351527RecruitingPhase 1
Testing a new drug for B-cell lymphoma that has returned
This trial tests an experimental drug (ICP-248) alone or with another antibody therapy for people with B-cell lymphomas that have returned or not responded to treatment. It aims to see if the drug is safe and if it can shrink or control the cancer.
Plantation, FloridaAges 18 years+ - NCT05422066RecruitingPhase 2
Selinexor with standard chemo for high-risk lymphoma
This Phase 2 trial studies selinexor added to standard R-CHOP chemotherapy in people with a high-risk type of diffuse large B-cell lymphoma (DLBCL) that is “germinal center B-cell” (GC). It aims to improve disease control in people who need stronger treatment at the start.
Guangzhou, GuangdongAges 18–75 - NCT07321301RecruitingPhase 2
CAR T-cell therapy for relapsed B-cell lymphoma or leukemia
This trial tests a new type of CAR T-cell therapy for people with B-cell lymphoma or leukemia that has not responded to standard treatments. The therapy uses a special delivery system to help the cells target and kill cancer cells.
Beijing, Beijing MunicipalityAges 14–85 - NCT07321652RecruitingPhase 3
Sonrotoclax plus zanubrutinib for untreated CLL or SLL
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Los Angeles, CaliforniaAges 65 years+ - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Louisville, KentuckyAges 18 years+ - NCT06788509Enrolling by invitationPhase 1
Continued treatment and safety monitoring after a parent study
This trial allows people who were already getting study treatment in a previous trial to keep receiving it and be monitored for safety. It is designed for those who have not had serious side effects or disease worsening.
Macquarie UniversityAges 18 years+ - NCT07566364RecruitingPhase 2
Mosunetuzumab for Chronic Lymphocytic Leukemia with Minimal Residual Disease
This study tests a new antibody drug called mosunetuzumab in patients with chronic lymphocytic leukemia (CLL) who have already tried other treatments and still have detectable leukemia cells in their bone marrow. The drug is designed to work in a way that might help your immune system fight the remaining cancer cells.
Houston, TexasAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Leukemia, Lymphocytic, Chronic, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia, lymphocytic, chronic, b-cell?
- Yes. Clin2 currently lists 134 recruiting leukemia, lymphocytic, chronic, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia, lymphocytic, chronic, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia, lymphocytic, chronic, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.